Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514108 | PMC |
| http://dx.doi.org/10.46989/001c.124277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Device profile of the Mobi-C artificial cervical disc: an overview of its safety and efficacy.
Expert Rev Med Devices
January 2025
UC Davis Health.
Introduction: The Mobi-C Cervical Disc Replacement is a motion preserving alternative to anterior cervical discectomy and fusion in properly indicated patients. In 2013, Mobi-C became the first cervical disc in the United States approved to treat more than one level of the cervical spine. The FDA determined Mobi-C to be statistically superior to fusion at 2 levels, based on the primary endpoint of a prospective, concurrently controlled and randomized multicenter clinical trial.
View Article and Find Full Text PDFClinical state and future directions of stem cell therapy in stroke rehabilitation.
Exp Neurol
December 2024
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Stroke Center, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:
Despite substantial advances in the acute management of stroke, it remains a leading cause of adult disability and mortality worldwide. Currently, the reperfusion modalities thrombolysis and thrombectomy benefit only a fraction of patients in the hyperacute phase of ischemic stroke. Thus, with the exception of vagal nerve stimulation combined with intensive physical therapy, there are no approved neuroprotective/neurorestorative therapies for stroke survivors.
View Article and Find Full Text PDFA Clinically Oriented Review of New Antipsychotics for Schizophrenia.
Neuropsychiatr Dis Treat
December 2024
Department of Medicine and Surgery, Kore University of Enna, Enna (EN), Italy.
Background: Currently available antipsychotics, mainly targeting the dopaminergic pathway, fail to address the complexity of schizophrenic symptoms and can lead to burdening adverse events. The need for innovative pharmacological options remains critical and research is now focusing on the development of non-dopaminergic antipsychotics. This review aims to summarize the current literature on the most promising non-dopaminergic new APs (muscarinic agonists, Trace Amine Associated Receptor 1 agonists, Glycine Transporter Type 1 inhibitors and 5-HT2A antagonists) and provide a clinically oriented overview of their efficacy, safety and potential use in schizophrenia.
View Article and Find Full Text PDFThe powerless bosses: the working day experience of bicycle messengers and its impact on their identities and wellbeing.
BMC Psychol
December 2024
Department of Psychosocial Science, University of Bergen, Christies gate 12. 5015, P.O. Box 7807, Bergen, NO-5020, Norway.
Background: Bicycle messengers in the online food delivery sector typically work on an on-demand basis, have digitally mediated relationships with their employer, and have very limited labor rights. In this study, we explore how bicycle messengers themselves experience their workday and how platform work influences their identity and wellbeing.
Method: We conducted qualitative interviews with ten bicycle messengers working for Foodora and Wolt in Bergen and Oslo, Norway.
"It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment.
Harm Reduct J
December 2024
Unit for Clinical Research on Addictions, Oslo University Hospital Health Trust, PB 4959 Nydalen, Oslo, 0424, Norway.
Background: Little attention has been paid to the experiences of clinicians and health personnel who provide heroin-assisted treatment (HAT). This study provides the first empirical findings about the clinicians' experiences of providing HAT in the Norwegian context.
Methods: 23 qualitative interviews were conducted with 31 clinicians shortly after HAT clinics opened in Norway's two largest cities: Oslo and Bergen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!